{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031145","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.120772+00:00","generated_at":"2026-06-08T08:14:38.449862+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GeoVax Q3 net loss widens to $8.4M; Phase 2 COVID vaccine enrollment completed","bullets":["Net loss $8.4M ($0.32/share) vs $3.97M ($0.17/share) in Q3 2022; cash $12.7M at Sep 30 vs $27.6M at Dec 31.","R&D expenses rose to $6.9M from $2.7M, driven by clinical trial costs for GEO-CM04S1 and Gedeptin.","Completed enrollment in Phase 2 trial of GEO-CM04S1 as a booster; initial data readout expected soon.","Signed multi-product license with ProBioGen for AGE1.CR.pIX suspension cell line to enhance MVA vaccine manufacturing.","Received U.S. patent allowances for Ebola, Marburg, Malaria, and HIV vaccines."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031145","json":"https://secwatch.observer/filing/0001437749-23-031145.json","markdown":"https://secwatch.observer/filing/0001437749-23-031145.md","text":"https://secwatch.observer/filing/0001437749-23-031145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774923031145/0001437749-23-031145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774923031145/govx20231108_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:14:38.449862+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9f1e8d7790811bb4385e4ea257a3f72ba3e2390","claim":"GeoVax Labs, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 8, 2023, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774923031145/0001437749-23-031145-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}